All News

A retrospective analysis of Canadian cases finds clinicians turn to a variety of therapies for chronic graft-vs-host disease (GVHD) if corticosteroids fail.

The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.

The fiscal 2025 budget will prioritize investments in rapid tests and antimicrobial drugs; women who were pregnant as teenagers are more likely to die before 31 years; leaders push for reform as part of spending bill for federal health agencies.

Patients had a lower risk of their diffuse large B-cell lymphoma (DLBCL) progressing if they had consolidative radiotherapy, a new report shows.

Arizona is well suited to benefit from its 1115 demonstration waiver requested from CMS because it already has a robust justice-involved reentry initiative called the Residential Substance Abuse Treatment (RSAT) Program, which is emerging as an archetype of successful reentry programs that can serve as a template for other states to emulate.

The approval fills a void for patients with CLL or SLL whose disease progresses after treatment with a BTK inhibitor and a BCL-2 inhibitor; until now, there has been no standard of care.

Since 2016, 5 targeted treatments have received accelerated approval from the FDA for use in Duchenne muscular dystrophy (DMD), and the total spend for just 3 of them is $3.1 billion.

The first medication for the treatment of nonalcoholic steatohepatitis (NASH) and liver fibrosis received accelerated approval. Previously, the only treatment available to patients was implementing lifestyle changes aimed at weight reduction.

After years of efforts to reduce low-value care, panelists at the 2024 Value-Based Insurance Design Summit proposed a new strategy: drawing a line in the sand that payers will not be on the hook for these services.

Posters suggest deuruxolitinib, a medication targeting specific cellular pathways, effectively promotes hair regrowth in patients with moderate to severe alopecia areata (AA) and results in minimal adverse events.

Over the course of the last 20 years, high-deductible health plans (HDHPs) have undergone an evolution. Today’s plans, with more high-value services covered predeductible, can improve care for people with chronic diseases, said panelists at the 2024 Value-Based Insurance Design (V-BID) Summit.

Patients with stage IV colorectal cancer (CRC) had lower overall and disease-free survival if they had a pelvic exenteration (PE) or cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).

The HHS Office for Civil Rights is investigating whether patient data were exposed in the cyberattack on Change Healthcare; a new study claims that the US’ high maternal mortality rates are the product of flawed data; HHS secretary is open to drug testing recipients of welfare.

Results come amid the FDA's review of chimeric antigen receptor (CAR) T-cell therapy.

Prevalence of hypertension remained 30% throughout the study period and was lower than expected, based on a lower threshold for hypertension endorsed by guidelines in 2017.

Results demonstrated a nonlinear relationship between admission heart rate (AHR) and in-hospital mortality in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and respiratory failure (RF).

A large-scale study suggests increased light at night exposure is linked to a higher risk of breast cancer, particularly in Asian populations and women with estrogen receptor-positive tumors (ER+).

Research presented at the American Academy of Dermatology Annual Meeting 2024 explored the impact of social determinants of health on hidradenitis suppurativa severity.

During a session of the 2024 V-BID Summit, panelists Stacie Dusetzina, PhD, and Inma Hernandez, PharmD, PhD, discussed how access to essential medications is curtailed not just by the longstanding complexities of insurance design but also by emerging threats such as supply chain weaknesses and cyberattacks.

This new analysis provides an optimistic outlook on the future of chronic lymphocytic leukemia (CLL) treatment and discoveries into the background behind CLL transformation into Richter syndrome.

Baricitinib and other oral JAK inhibitors show promise as effective treatments for moderate-to-severe alopecia areata (AA), with fewer adverse effects compared with traditional options.

Following these positive 36-week results, Silence Therapeutics plans to announce 48-week results of the ongoing ALPACAR-360 study in Q2 of 2024.

Study findings show that scores on the Psoriasis Area and Severity Index and the Dermatology Quality of Life Index are correlated in patients with psoriasis across several continents, but factors affecting each of these scores are different across countries.

Telehealth, which increased 63-fold from 2019 to 2020, has potential for managing and delivering care to patients with rheumatic diseases.

Compared with matched controls, patients with myeloproliferative neoplasms (MPNs) had a higher risk of developing thrombosis, hemorrhage, and leukemic transformation, according to a longitudinal cohort study.

A deep learning model may be able to outperform ophthalmologists in predicting neovascular age-related macular degeneration (nAMD) recurrence.

An appeals court rules against the Pharmaceutical Research and Manufacturers of America in a 340B contract pharmacy dispute; for-profit investors’ acquisition of nursing homes has raised concerns about the quality of care provided in these facilities; President Joe Biden’s proposed budget for 2025 includes changes that would do away with the current system of biosimilar interchangeability.

Incidence and prevalence of myasthenia gravis in the US has increased surprisingly since last examined more than 20 years ago.